Annals of Surgical Oncology 2020 October [Link] Akifumi Nakamura, Nobuyuki Kondo, Toru Nakamichi, Masaki Hashimoto, Teruhisa Takuwa, Seiji Matsumoto, Kozo Kuribayashi, Takashi Kijima, Seiki Hasegawa Abstract Background: A few studies have reported the incidence and clinical implications of complications after pleurectomy/decortication (P/D). Objective: The aim of this study was to assess the details of complications…

Read More

Annals of Surgical Oncology 2020 October 18 [Link] David Roife, Benjamin D Powers, Mohammad Y Zaidi, Charles A Staley, Jordan M Cloyd, Ahmed Ahmed, Travis Grotz, Jennifer Leiting, Keith Fournier, Andrew J Lee, Jula Veerapong, Joel M Baumgartner, Callisia Clarke, Sameer H Patel, Ryan J Hendrix, Laura Lambert, Daniel E Abbott, Courtney Pokrzywa, Byrne Lee,…

Read More

Thoracic Cancer 2020 October 8 [Link] Oscar Arrieta, Francisco Lozano-Ruiz, Monika Blake-Cerda, Rodrigo Catalán, Luis Lara-Mejía, Miguel Ángel Salinas, Federico Maldonado-Magos, José F Corona-Cruz Abstract Background: Treatment of malignant pleural mesothelioma (MPM) represents a major challenge for oncologists. Multimodality treatment, which generally involves induction chemotherapy, surgery and radiotherapy have recently shown promising results. The aim…

Read More

International Journal of Surgery Case Reports 2020 [Link] Naveen Padmanabhan, Haruaki Ishibashi, Kazurou Nishihara, Shouzou Sako, Kanji Katayama, Satoshi Wakama, Yasuyuki Kamada, Yutaka Yonemura Abstract Background: Multicystic Peritoneal mesothelioma is a rare and distinct variety of peritoneal mesothelioma with borderline malignant potential. Conventional Tumor bulking has been associated with recurrence of 45-50 %. Hence a…

Read More

Expert Opinion on Pharmacotherapy 2020 August 12 [Link] Yutaka Yonemura, Haruaki Iahibashi, Shouzou Sako, Akiyoshi Mizumoto, Nobuyuki Takao, Masumi Ichinose, Shunsuke Motoi, Yang Liu, Satoshi Wakama, Yasuyuki Kamada, Kazurou Nishihara Abstract Introduction: A new treatment strategy involving cytoreductive surgery (CRS) combined with perioperative intraperitoneal (IP) chemotherapy was proposed in 1999 by the Peritoneal Surface Oncology…

Read More

BMC Research Notes 2020 July 29 [Link] Martin Lehnert, Daniel G Weber, Dirk Taeger, Irina Raiko, Jens Kollmeier, Susann Stephan-Falkenau, Thomas Brüning, Georg Johnen, MoMar-Study Group Abstract Objective: Calretinin is a well-known immunohistochemical tissue marker in the diagnosis of malignant mesothelioma. Promising results also indicate the use in early detection. In the present cross-sectional survey,…

Read More

Current Drug Targets 2020 July 18 [Link] Lei Cheng, Li Na, Xiao-Ling Xu, Wei-Min Mao Abstract Malignant pleural mesothelioma (MPM) is a remarkably aggressive thoracic malignancy with a limited survival of only 5-12 months. However, MPM still remains unresponsive to conventional standards of treatment, including pleurectomy and decortication, extrapleural pneumonectomy for resectable disease with or…

Read More

Lung Cancer 2020 May 30 [Link] Andrew B Thompson, Thomas J Quinn, Zaid A Siddiqui, Muayad F Almahariq, Inga S Grills, Craig W Stevens Abstract Introduction: Malignant pleural mesothelioma (MPM) is a devastating disease with poor survival outcomes for most patients. Optimizing therapeutic approaches is thus vital, but has been hampered by a dearth of…

Read More

Annals of Surgical Oncology 2020 January [Link] Zubair Bayat, Emily L Taylor, Danielle A Bischof, J Andrea McCart, Anand Govindarajan Abstract Background: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) can be associated with decreases in quality of life (QOL). Bowel-related QOL (BR-QOL) after CRS-HIPEC has not been previously studied. The objectives of the current study…

Read More